310 N. Main St., Suite 301
Chelsea, MI 48118 . USA
734-433-9670

INTERNATIONAL DISCOVERY SERVICES & CONSULTING

Pharmacum Nuntius:

January 2013, Volume II, Issue I

While enjoying your afternoon tea we bring you a mix of interesting articles spanning fund raising, Diabetes, Melanoma, Targeting Multiple Pathways, and on to the latest marked drug for Myeloid Leukemia. Enjoy!

Mark Creswell, CEO

Funding Opportunity: Optimizing your funding applications

Finding funding opportunities and maximizing the chance of success remains a high priority for many of our clients and those who will become our clients. We continue to highlight organizations which bring value in this area. The FreeMind group is a consulting organization with expertise in the field of non-dilutive funding acquisition. Their scientific research analysts and scientific writers assist clients to secure grants and contracts from non-dilutive sources. While their primary focus is optimizing NIH and DOD applications they also help clients get funding from CDC, FDA, NSF, NIST, Bill and Melinda Gates Foundation, Komen Foundation and many others. For more information check out their website.



Four Perspectives in Diabetes: Patents, Physicians, Payers and Financial analysts

In a recent article, Lisa Rotenstien et.al. provide an excellent high level overview of diabetes therapies “today” and asks a key question, how close are we to an ideal Diabetes treatment? The authors provide perspectives from patents, physicians, payers and financial analysts as well as a review of current therapies and treatments on the horizon. They conclude that there is still significant opportunity (both therapeutically and

commercially) in this area of research. They also comment that “current diabetes treatments and those in late-stage development still have significant drawbacks such as limited efficacy, unwanted side effects, and inconvenient dosing.” Click to view the article.



SMURF2 & Melanoma:

With the goal of improving approaches for the treatment of deadly Melanoma cancers, researchers at the University of Manchester discovered that “increased expression of MITF, PAX3, and SMURF2 allows melanoma cells to escape the proapoptotic effects of MEK inhibition.” The protein SMURF2 was reduced in primary resistant cell lines using siRNA techniques, while the cells were treated with MEK inhibitors. This combination led to an overall increase in cell kill both in-vitro and in-vivo. SMURF2 is believed to play a specific role in melanoma. Click here for the summary article and Click here for the full article.



To be Selective or not to be Selective: One Drug, Multiple Targets:

How many times have you run your lead compound through a screening panel to assure selectivity? It’s difficult enough to achieve selectivity against a single target…how about selectively hitting a group of targets. Check out this article on Medicinal Chemistry News that discusses such work progressing at both the North Carolina School of Medicine and the University of Dundee, in the U.K. utilizing computational chemistry methods in the design of new compounds. Note: This is a free article, but readers will have to register to the Medicinal Chemistry News website in order to read the article.

New Myeloid Leukemia Drug:

ARIAD’s new Leukemia drug, Iclusig® (Ponatinib) has been granted accelerated approval. Iclusig was developed using structure based drug design to inhibit native and mutant isoforms of BCR-ABL including the most common mutation, T315I. Iclusig will be used for CML patients resistant to TKI therapy as well as Ph-ALL that are resistant to prior TKI therapy.

For more information about IDSC:

Click on our website: WWW.IDSCBIOTECHNETWORK.COM

A Spotlight on IDSC's Director...Alex Bridges: Oncology & Metabolic Diseases

Dr. Bridges has had a 28 year big pharma, biotech, and consulting career following six years in academia. During his term as Oncology Discovery Executive Director at Pfizer Alex was responsible for the nomination of three clinical candidates; including a second generation pan-ErbB irreversible inhibitor, PF 0299804, which is currently in Phase III clinical trials for lung cancer and a CDK4/6-selective inhibitor, PD 0332991, which is expected to start Phase III in 2013. In addition, Alex was a member of the senior discovery management team, and a member of the worldwide Discovery Management Committee. Alex was instrumental in initiating and leading the Metabolic Disease Discovery program for Warner-Lambert/Parke-Davis Research. Alex retains his passion and expertise for medicinal chemistry and synthetic chemistry. More...

FROM HIT TO THE CLINIC: IDSC IS YOUR DRUG DISCOVERY & DEVELOPMENT PARTNER

www.idscbiotechnetwork.com